How long can you generally live taking Regorafenib?

Regorafenib(Regorafenib) is a once-daily prescription anticancer drug used to treat colon cancer that has spread to other parts of the body (CRC), previously treated gastrointestinal stromal tumors (GIST) and hepatocellular carcinoma (HCC), compared to placebo, it has been shown to help some patients live longer and prevent cancer progression.

In clinical trials of patients with metastatic CRC (mCRC), regorafenib increased overall survival, or the length of time from when a patient joined the study to death from any cause, compared with placebo, with the median survival of regorafenib being 6.4 months. In clinical trials of gastrointestinal stromal tumors, patients taking regorafenib experienced a median progression-free survival (PFS) of 4.8 months, with a 73% reduction in the risk of disease progression or death. In clinical trials for HCC, the average survival time of patients taking regorafenib was 10.6 months.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).